Cefprozil dry suspension

This product is a second-generation cephalosporin drug with a broad-spectrum antibacterial effect. The bactericidal mechanism of this drug is to bind to penicillin-binding proteins (PBPs) on the bacterial cell membrane, hinder the synthesis of bacterial cell walls, and thus cause the bacteria to dissolve and die. In vitro tests have shown that cefprozil has a significant effect on Gram-positive aerobic bacteria such as Staphylococcus aureus (including β-lactamase-producing strains), Streptococcus pneumoniae, and Streptococcus pyogenes, and has an inhibitory effect on Enterococcus tenacious, Listeria monocytogenes, Staphylococcus epidermidis, Staphylococcus saprophyticus, Staphylococcus warnei, Streptococcus agalactiae, Streptococcus C, D, F, G groups, and viridans streptococci. It is ineffective against methicillin-resistant Staphylococcus aureus and Enterococcus faecalis. It is highly sensitive to the gram-negative aerobic bacteria Haemophilus influenzae (including β-lactamase-producing strains) and Moraxella catarrhalis (including β-lactamase-producing strains). It can inhibit the growth and reproduction of Diversus Citrobacter Escherichia coli, Klebsiella pneumoniae, Neisseria gonorrhoeae (including β-lactamase-producing strains), Proteus mirabilis, Salmonella, Shigella and Vibrio. It has no antibacterial effect on most strains of Acinetobacter, Enterobacter, Morganella morganii, Proteus vulgaris, Providencia and Pseudomonas. It has a certain inhibitory effect on melanin-producing Bacillus, Clostridium difficile, Clostridium perfringens, Fusobacterium, Streptococcus and Propionibacterium acnes among anaerobic bacteria, and has no antibacterial effect on most strains of Bacillus fragilis. Toxicological studies: Long-term carcinogenicity studies have not been conducted. No mutagenic effects were found in the Ames test conducted in Salmonella or Escherichia coli and the chromosome aberration test conducted in Chinese hamster ovary cells. In the mouse bone marrow micronucleus test, no chromosomal aberrations were found in oral administration of doses up to 30 times the highest human dose (calculated as mg/m2). No damage to reproductive capacity was found in male or female rats given cefprozil orally at doses up to 18.5 times the highest human dose (calculated as mg/m2).

Cefprozil, of which the cis isomer accounts for about 90%.

This product is off-white, light yellow or light orange powder, which becomes a pink suspension after adding water and shaking.

For mild and moderate infections caused by sensitive bacteria. Upper respiratory tract infection, purulent streptococcal pharyngitis/tonsillitis. Note: Intramuscular penicillin should be selected for the treatment and prevention of streptococcal infections (including the prevention of rheumatic fever). Although cefprozil is generally effective in clearing purulent streptococci in the nasopharynx, there is currently no data available for the use of cefprozil in the prevention of secondary rheumatic fever. Otitis media caused by Streptococcus pneumoniae, Haemophilus influenzae (including β-lactamase-producing strains), and Moraxella catarrhalis (including β-lactamase-producing strains). Acute sinusitis caused by Streptococcus pneumoniae, Haemophilus influenzae (including β-lactamase-producing strains), and Moraxella catarrhalis (including β-lactamase-producing strains). Lower respiratory tract infection, secondary bacterial infection of acute bronchitis and acute exacerbation of chronic bronchitis caused by Streptococcus pneumoniae, Haemophilus influenzae (including β-lactamase-producing strains), and Moraxella catarrhalis (including β-lactamase-producing strains). Skin and skin tissue infections caused by Staphylococcus aureus (including penicillinase-producing strains) and Streptococcus pyogenes are uncomplicated, but abscesses usually require surgical drainage.

Oral. Preparation method: Add appropriate amount of warm boiled water (at least 20ml per package) to prepare the solution, shake well and take. The stability of the solution after preparation has not been investigated, and it is recommended to prepare and use it immediately. For adults (13 years old or above) with upper respiratory tract infections, take 0.5g each time, once a day; for lower respiratory tract infections, take 0.5g each time, twice a day; for skin or skin soft tissue infections, take 0.5g per day, divided into 1 or 2 times; for severe cases, take 0.5g each time, twice a day. For upper respiratory tract infections in children aged 2 to 12 years, take 7.5mg/kg body weight each time, twice a day; for skin or skin soft tissue infections, take 20mg/kg body weight each time, once a day. For otitis media in infants from 6 months to children aged 12 years, take 15mg/kg body weight each time, twice a day; for acute sinusitis, generally take 7.5mg/kg each time

1. The adverse reactions of ceftriaxone are similar to those of other oral cephalosporins, mainly gastrointestinal reactions, including diarrhea, nausea, vomiting and abdominal pain. Allergic reactions may also occur, most commonly rash and urticaria. Allergic reactions are more common in children than in adults, and often occur within a few days after the start of treatment and disappear within a few days after stopping the drug. Other adverse reactions are rare, including: Hepatobiliary system: AST (aspartate aminotransferase) and ALT (alanine aminotransferase) increase. Occasionally, alkaline phosphatase and bilirubin increase. Cholestatic jaundice is rare. Central nervous system: dizziness, hyperactivity, headache, mental tension, insomnia. Occasionally, drowsiness. All these reactions are reversible. Blood system: leukopenia, eosinophilia. Kidney: increased blood urea nitrogen and increased blood creatinine.

Contraindicated in patients allergic to cephalosporins.

Precautions for children: There is no data on the safety and efficacy of this drug in pediatric patients under 6 months old. However, there have been reports of other cephalosporins accumulating in newborns (due to the extended half-life of drugs in children of this age group). Precautions for pregnancy and lactation: 1. Use with caution in pregnant women. 2. A small amount of drug (<0.3% of the dose) can be detected in breast milk when a lactating woman takes 1g of this drug orally at one time. The average concentration over 24 hours is 0.25mg/L to 3.3mg/L. Since the effect of this drug on infants is not yet clear, lactating women should be cautious when taking this drug or stop breastfeeding. Precautions for the elderly: In the elderly (≥65 years old), the average area under the drug-time curve (AUC) of this drug increases by 35% to 60% relative to that of young adults. Elderly patients should adjust the dosage or medication interval according to their renal function under the guidance of a physician.

Nephrotoxicity has been reported with the combined use of aminoglycosides and cephalosporins. Coadministration with probenecid doubles the AUC of cefprozil. Drug/Laboratory Test Interactions Cephalosporins can cause false-positive reactions in urine glucose reduction tests [Benedict or Feling's reagents or copper sulfate tablets (Clinitest® tablets)] but not in urine glucose enzymatic tests (e.g., Tes-Tape® urine glucose test strips). These drugs can cause false-negative glucose ferrocyanide reactions. Cefprozil in the blood does not interfere with the determination of creatinine in the blood or urine by the alkaline picrate method.

Keep away from light, seal tightly, and store in a cool and dry place. Validity period: two years

0.125g

24 months

Nanjing Yewin Pharmaceutical Co., Ltd.

• Founded in:

  2002-12-24

• Address:

  No. 18, Xingang Avenue, Nanjing Economic and Technological Development Zone

• Tax NO.:

  91320192745358509L

• Registered Funds:

  15 million yuan

• Website:

  Log in to view

• Email:

  Log in to view